Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.

被引：3
|
作者：
Goyal, Lipika [1 ]
Meric-Bernstam, Funda [2 ]
Hollebecque, Antoine [3 ]
Morizane, Chigusa [4 ]
Valle, Juan W. [5 ]
Karasic, Thomas B. [6 ]
Abrams, Thomas A. [7 ]
Kelley, Robin Kate [8 ]
Cassier, Philippe [9 ]
Furuse, Junji [10 ]
Klumpen, Heinz-Josef [11 ]
Chang, Heung-Moon [12 ]
Chen, Li-Tzong [13 ]
Komatsu, Yoshito [14 ]
Masuda, Kunihiro [15 ]
Ahn, Daniel [16 ]
He, Yaohua [17 ]
Soni, Nital [18 ]
Benhadji, Karim A. [17 ]
Bridgewater, John A. [19 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Manchester, Manchester, Lancs, England
[6] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Ctr Leon Berard, Lyon, France
[10] Kyorin Univ, Tokyo, Japan
[11] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[12] Asan Med Ctr, Seoul, South Korea
[13] Natl Inst Canc Res, Tainan, Taiwan
[14] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[15] Tohoku Univ, Sendai, Miyagi, Japan
[16] Mayo Clin, Phoenix, AZ USA
[17] Taiho Oncol Inc, Princeton, NJ USA
[18] Taiho Oncol, Princeton, NJ USA
[19] UCL, Canc Inst, London, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT010
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
    Tsujie, Masanori
    Iwai, Tomohisa
    Kubo, Shoji
    Ura, Takashi
    Hatano, Etsuro
    Sakai, Daisuke
    Takeda, Yutaka
    Kaibori, Masaki
    Kobayashi, Tomoe
    Katanuma, Akio
    Katayose, Yu
    Fukase, Koji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 911 - 917
  • [32] Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements
    Beri, Nina
    FUTURE ONCOLOGY, 2022, 18 (11) : 1391 - 1403
  • [33] FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
    Javle, Milind M.
    Shaib, Walid Labib
    Braun, Stephan
    Engelhardt, Marc
    Borad, Mitesh J.
    Abou-Alfa, Ghassan K.
    Boncompagni, Andrea
    Friedmann, Silke
    Gahlemann, Christoph Georg
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Diverse Landscape of Fibroblast Growth Factor Receptor 2 (FGFR2) Rearrangement Partners in Intrahepatic Cholangiocarcinoma (iCCA)
    Silverman, I. M.
    Reeser, J. W.
    Wing, M. R.
    Krook, M. A.
    Roychowdhury, S.
    Newton, R. C.
    Burn, T. C.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1185 - 1185
  • [35] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
    Mirchia, Kanish
    Gay, Laurie
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, J. Keith
    Nhu Ngo
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Chung, Jon
    Ali, Siraj
    Schrock, Alexa
    Reddy, Venkataprasanth
    Miller, Vincent
    Corona, Robert
    Ross, Jeffrey
    MODERN PATHOLOGY, 2019, 32
  • [36] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
    Mirchia, Kanish
    Gay, Laurie
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, J. Keith
    Nhu Ngo
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Chung, Jon
    Ali, Siraj
    Schrock, Alexa
    Reddy, Venkataprasanth
    Miller, Vincent
    Corona, Robert
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2019, 99
  • [37] Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
    Walden, Daniel
    Eslinger, Cody
    Bekaii-Saab, Tanios
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [38] Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
    White, Kathryn
    Anwar, Ahmed I.
    Jin, Kevin
    Bollich, Victoria
    Kelkar, Rucha A.
    Talbot, Norris C.
    Klapper, Rachel J.
    Ahmadzadeh, Shahab
    Viswanath, Omar
    Varrassi, Giustino
    Shekoohi, Sahar
    Kaye, Alan D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [39] Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
    Meric-Bernstam, Funda
    Bahleda, Rastislav
    Hierro, Cinta
    Sanson, Marc
    Bridgewater, John
    Arkenau, Hendrik-Tobias
    Tran, Ben
    Kelley, Robin Kate
    Park, Joon Oh
    Javle, Milind
    He, Yaohua
    Benhadji, Karim A.
    Goyal, Lipika
    CANCER DISCOVERY, 2022, 12 (02) : 402 - 415
  • [40] Characterization of two novel oncogenic FGFR2 fusions sensitive to the FGFR-selective inhibitor Debio 1347 in cholangiocarcinoma
    Vaslin, Anne
    Rigotti, Stefania
    Lembrez, Nathalie
    Vuagniaux, Gregoire
    Moulon, Corinne
    Tanaka, Hiroaki
    CANCER RESEARCH, 2015, 75
12345